Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY24 results · Oct–Dec 2023
Sun Pharma Advanced Research Company reported revenue from operations of ₹13.86 crore and net loss of ₹99.65 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 13.86 | — | — | 21.18 | −34.6% |
| Other income | 6.39 | — | — | 8.49 | −24.7% |
| Total income | 20.25 | — | — | 29.67 | −31.7% |
| Profit before tax | (99.65) | — | — | (86.42) | Loss widened |
| Net profit for the period | (99.65) | — | — | (86.42) | Loss widened |
| Attributable to shareholders of the company | (99.31) | — | — | (86.42) | Loss widened |
| EPS, basic (₹) | (3.07) | — | — | (2.66) | Loss widened |
| Net margin (%) | -719.0 | — | -408.0 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 13.86 | 131.09 | −89.4% | 21.18 | −34.6% |
| Other income | 6.39 | 0.03 | 213x | 8.49 | −24.7% |
| Total income | 20.25 | 131.12 | −84.6% | 29.67 | −31.7% |
| Profit before tax | (99.65) | 10.15 | Turned loss | (86.42) | Loss widened |
| Net profit for the period | (99.65) | 10.15 | Turned loss | (86.42) | Loss widened |
| EPS, basic (₹) | (3.07) | 0.37 | not comparable | (2.66) | Loss widened |
| Net margin (%) | -719.0 | 7.7 | -408.0 |
Consolidated
- Filed with BSE
- 19 Feb 2024, 18:10 IST
- Board meeting
- 05 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Feb 2024, 18:10 IST
- Board meeting
- 05 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE